Evolus, Inc. (NASDAQ:EOLS) Major Shareholder Medytox Inc. Sells 15,300 Shares

Evolus, Inc. (NASDAQ:EOLSGet Rating) major shareholder Medytox Inc. sold 15,300 shares of the company’s stock in a transaction dated Thursday, September 8th. The shares were sold at an average price of $10.39, for a total transaction of $158,967.00. Following the sale, the insider now directly owns 7,422,352 shares of the company’s stock, valued at approximately $77,118,237.28. The sale was disclosed in a filing with the SEC, which is available at this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Medytox Inc. also recently made the following trade(s):

  • On Monday, August 1st, Medytox Inc. sold 26,000 shares of Evolus stock. The shares were sold at an average price of $13.28, for a total transaction of $345,280.00.

Evolus Stock Performance

Shares of EOLS stock opened at $10.72 on Tuesday. The firm’s 50 day moving average price is $11.01 and its 200-day moving average price is $11.30. The company has a debt-to-equity ratio of 1.53, a quick ratio of 2.36 and a current ratio of 2.60. Evolus, Inc. has a one year low of $5.06 and a one year high of $14.34. The firm has a market cap of $601.34 million, a P/E ratio of -7.60 and a beta of 2.01.

Hedge Funds Weigh In On Evolus

Several large investors have recently made changes to their positions in EOLS. Northern Trust Corp lifted its holdings in shares of Evolus by 0.5% in the 4th quarter. Northern Trust Corp now owns 309,933 shares of the company’s stock worth $2,018,000 after acquiring an additional 1,643 shares during the last quarter. ProShare Advisors LLC acquired a new position in shares of Evolus in the 4th quarter worth approximately $98,000. Schroder Investment Management Group lifted its holdings in shares of Evolus by 37.8% in the 4th quarter. Schroder Investment Management Group now owns 2,317,281 shares of the company’s stock worth $15,085,000 after acquiring an additional 636,109 shares during the last quarter. Soleus Capital Management L.P. lifted its holdings in shares of Evolus by 95.8% in the 4th quarter. Soleus Capital Management L.P. now owns 1,258,889 shares of the company’s stock worth $8,195,000 after acquiring an additional 615,955 shares during the last quarter. Finally, Point72 Asset Management L.P. purchased a new stake in Evolus during the 4th quarter worth approximately $2,022,000. 50.60% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Needham & Company LLC initiated coverage on shares of Evolus in a report on Thursday, June 23rd. They issued a “buy” rating and a $18.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $15.33.

About Evolus

(Get Rating)

Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

Featured Stories

Insider Buying and Selling by Quarter for Evolus (NASDAQ:EOLS)

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.